The Japan Times - High hopes for nasal Covid vaccines despite 'disappointing' trial

EUR -
AED 3.839032
AFN 78.318295
ALL 98.686181
AMD 418.630098
ANG 1.881327
AOA 955.800527
ARS 1094.340711
AUD 1.653056
AWG 1.881379
AZN 1.776484
BAM 1.96609
BBD 2.10768
BDT 127.301836
BGN 1.95521
BHD 0.393966
BIF 3088.952288
BMD 1.045211
BND 1.416338
BOB 7.213608
BRL 6.192247
BSD 1.043856
BTN 90.188095
BWP 14.488773
BYN 3.416238
BYR 20486.127443
BZD 2.096843
CAD 1.497813
CDF 2974.669187
CHF 0.945842
CLF 0.037408
CLP 1032.197824
CNY 7.568896
CNH 7.571683
COP 4417.331682
CRC 526.79962
CUC 1.045211
CUP 27.69808
CVE 110.642972
CZK 25.098667
DJF 185.893259
DKK 7.460462
DOP 64.058834
DZD 140.778224
EGP 52.565522
ERN 15.678159
ETB 133.481592
FJD 2.408426
FKP 0.860822
GBP 0.842409
GEL 2.994518
GGP 0.860822
GHS 15.81495
GIP 0.860822
GMD 75.255015
GNF 9026.836922
GTQ 8.06756
GYD 218.395023
HKD 8.137283
HNL 26.57679
HRK 7.713182
HTG 136.42605
HUF 409.69429
IDR 16898.024029
ILS 3.734135
IMP 0.860822
INR 90.199058
IQD 1367.445216
IRR 43990.30736
ISK 145.880122
JEP 0.860822
JMD 164.110625
JOD 0.741576
JPY 162.260058
KES 135.187213
KGS 91.401889
KHR 4203.359256
KMF 493.745458
KPW 940.689642
KRW 1496.219752
KWD 0.321998
KYD 0.869955
KZT 543.516327
LAK 22759.531956
LBP 93480.648443
LKR 311.701834
LRD 206.696102
LSL 19.376608
LTL 3.086235
LVL 0.632237
LYD 5.137501
MAD 10.437907
MDL 19.46832
MGA 4893.717616
MKD 61.575094
MMK 3394.803205
MNT 3551.625676
MOP 8.375451
MRU 41.579439
MUR 48.455717
MVR 16.094183
MWK 1810.183838
MXN 21.211368
MYR 4.590463
MZN 66.78705
NAD 19.376422
NGN 1626.358483
NIO 38.411218
NOK 11.724064
NPR 144.300952
NZD 1.830363
OMR 0.402336
PAB 1.043861
PEN 3.882188
PGK 4.190355
PHP 61.014694
PKR 290.959273
PLN 4.213021
PYG 8254.118238
QAR 3.8054
RON 4.975724
RSD 117.116883
RUB 104.389962
RWF 1449.050156
SAR 3.920503
SBD 8.828422
SCR 14.91201
SDG 628.171368
SEK 11.452702
SGD 1.409059
SHP 0.860822
SLE 23.731231
SLL 21917.543254
SOS 596.638199
SRD 36.692093
STD 21633.748813
SVC 9.134028
SYP 13589.827995
SZL 19.384219
THB 35.214217
TJS 11.425531
TMT 3.658237
TND 3.332886
TOP 2.447983
TRY 37.312999
TTD 7.096105
TWD 34.121421
TZS 2649.608991
UAH 43.843475
UGX 3847.123903
USD 1.045211
UYU 45.68607
UZS 13549.156159
VES 58.754499
VND 26198.203283
VUV 124.089499
WST 2.927454
XAF 658.205521
XAG 0.033877
XAU 0.000376
XCD 2.824734
XDR 0.804348
XOF 658.199202
XPF 119.331742
YER 260.363701
ZAR 19.24459
ZMK 9408.155357
ZMW 29.045947
ZWL 336.557382
  • RBGPF

    61.2800

    61.28

    +100%

  • AZN

    0.4000

    68.6

    +0.58%

  • NGG

    0.6600

    60.71

    +1.09%

  • CMSC

    -0.0050

    23.485

    -0.02%

  • SCS

    0.0200

    11.6

    +0.17%

  • BTI

    0.4800

    37.05

    +1.3%

  • CMSD

    -0.0900

    23.87

    -0.38%

  • GSK

    0.6200

    34.05

    +1.82%

  • BP

    0.3600

    31.49

    +1.14%

  • RIO

    0.4400

    61.56

    +0.71%

  • RELX

    0.1300

    49.39

    +0.26%

  • RYCEF

    0.2800

    7.55

    +3.71%

  • JRI

    0.0200

    12.55

    +0.16%

  • BCE

    0.0700

    23.22

    +0.3%

  • BCC

    0.5300

    128.45

    +0.41%

  • VOD

    0.0200

    8.4

    +0.24%

High hopes for nasal Covid vaccines despite 'disappointing' trial
High hopes for nasal Covid vaccines despite 'disappointing' trial / Photo: TIM SLOAN - AFP/File

High hopes for nasal Covid vaccines despite 'disappointing' trial

Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.

Text size:

By entering the body the same way as the virus, nasal vaccines aim to build immunity in the mucous membrane that lines the nose and mouth.

This could block people from getting infected in the first place -- and also potentially hamper those who have Covid from spreading it further.

That would represent a huge boost compared to traditional shots in the arm, which have proved very effective at preventing severe Covid but perform far less well when it comes to stopping transmission.

Last month China became the first country to approve a needle-free Covid vaccine, an aerosolised mist inhaled through the nose and mouth using a nebuliser device, while India greenlit a homegrown nasal drop vaccine days later.

With some wondering when Western nations would catch up, last week Oxford researchers revealed the results of a phase 1 trial for a simple nasal spray using the AstraZeneca vaccine.

However, the vaccine promoted mucosal antibodies only in a minority of the participants, and the immune responses were weaker compared to those from traditional vaccines, according to a study published in the journal eBioMedicine.

- Don't be 'too downhearted' -

"The nasal spray did not perform as well in this study as we had hoped," said the trial's chief investigator, Sandy Douglas of Oxford University.

"This was quite different from recent data from China, which has suggested good results can be achieved by delivery of a similar vaccine deep into the lungs with a more complex nebuliser device," Douglas said in a statement.

"One possibility is simply that the majority of the nasal spray vaccine ends up being swallowed and destroyed in the stomach -- delivery to the lungs could avoid that."

Connor Bamford, a virologist at Queen's University Belfast, told AFP that it was important to "not be too downhearted" about the AstraZeneca results.

He said that working out exactly why the nasal spray fell short could help researchers discover how to make a future version more effective.

Unlike AstraZeneca, successful nasal vaccines used for other diseases such as polio, rotavirus and influenza are all live vaccines, which means they replicate inside the nose, Bamford said, potentially pointing a way forwards for researchers.

Eric Tartour, an immunologist at the European Hospital Georges Pompidou in Paris, said that while the AstraZeneca results "are indeed disappointing", he did not think the news "dampens hope for nasal vaccines".

It was "reassuring" that the AstraZeneca, Chinese and Indian nasal vaccines have not shown any serious side effects, he added.

Around 100 different intranasal Covid vaccines are under development worldwide, according to analysis by health data firm Airfinity and Nature last month, with some 20 being tested on humans.

Russia and Iran have also approved nasal vaccines. However, like China and India, they have not published trial data showing that their vaccines stop transmission in a peer-reviewed journal.

And with falling inoculation rates worldwide leading some countries to destroy millions of expired doses, the demand for a new Covid vaccine remains unclear.

- 'Wake up and lead' -

For example, in 2020 France's Pasteur Institute and biotech firm TheraVectys developed a nasal vaccine candidate that was found to block transmission and produce antibodies for different variants in tests on animals, according to chief scientific officer Pierre Charneau.

However, the vaccine has not "aroused enough interest from funding agencies or 'Big Pharma' to hold trials on humans," so the firm has turned its focus back towards cancer vaccines, Charneau said.

US biotech firm Meissa Vaccines has developed a nasal vaccine shown to produce an immune response in phase 1 trials on humans, said its chief scientific officer Martin Moore.

So how long could it take for such a nasal vaccine to be made available to the public? It depends, Moore said.

He called for the world to put similar resources into creating a nasal vaccine as it did into the first round of Covid jabs, which were developed and deployed en masse in less than a year -- the fastest rate in history.

"If there was a Warp Speed 2.0, and there should be, our vaccine could be available to the public with a similar timeline," Moore said.

"Reducing transmission is the best way to gain control over the virus," Moore said. "The challenge is proving that a nasal vaccine can actually do this," he added.

"The upside to our health and economies is enormous. Western countries need to wake up and lead."

Y.Watanabe--JT